Authors

Yong Lin, Department of Laboratory Medicine, Huashan Hospital of Fudan University, Shanghai, China; The Department of Clinical Laboratory, Central Laboratory, Jing'an District Centre Hospital of Shanghai, Huashan Hospital of Fudan University Jing'An Branch, Shanghai, China
Xin Ge, State Key Lab of Reproductive Medicine, Key Lab of Human Functional Genomics of Jiangsu Province, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention, and Treatment, Department of Pathology, Cancer Center, Nanjing Medical University, Nanjing, China ; Ninggao Personalized Medicine and Technology Innovation Center, Nanjing, ChinaFollow
Yiyang Wen, State Key Lab of Reproductive Medicine, Key Lab of Human Functional Genomics of Jiangsu Province, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention, and Treatment, Department of Pathology, Cancer Center, Nanjing Medical University, Nanjing, China
Zhu-Mei Shi, State Key Lab of Reproductive Medicine, Key Lab of Human Functional Genomics of Jiangsu Province, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention, and Treatment, Department of Pathology, Cancer Center, Nanjing Medical University, Nanjing, China; Department of Neurosurgery, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China
Qiu-Dan Chen, The Department of Clinical Laboratory, Central Laboratory, Jing'an District Centre Hospital of Shanghai, Huashan Hospital of Fudan University Jing'An Branch, Shanghai, ChinaFollow
Min Wang, State Key Lab of Reproductive Medicine, Key Lab of Human Functional Genomics of Jiangsu Province, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention, and Treatment, Department of Pathology, Cancer Center, Nanjing Medical University, Nanjing, China
Ling-Zhi Liu, Lab of Reproductive Medicine, Department of Pathology, Cancer Center, Nanjing Medical University, Nanjing, Jiangsu, China; Department of Pathology, Anatomy and Cell Biology, and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, United StatesFollow
Bing-Hua Jiang, State Key Lab of Reproductive Medicine, Key Lab of Human Functional Genomics of Jiangsu Province, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention, and Treatment, Department of Pathology, Cancer Center, Nanjing Medical University, Nanjing, China; Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, United StatesFollow
Yuan Lu, Department of Laboratory Medicine, Huashan Hospital of Fudan University, Shanghai, China

Document Type

Article

Publication Date

9-27-2016

Comments

This article has been peer reviewed. It was published in: Oncotarget.

Volume 7, Issue 43, 2016, Pages 70857-70868.

The published version is available at DOI: 10.18632/oncotarget.12268

Copyright © 2016 The Authors

Abstract

Pancreatic adenocarcinoma is one of the most leading causes of cancer-related deaths worldwide. Although recent advances provide various treatment options, pancreatic adenocarcinoma has poor prognosis due to its late diagnosis and ineffective therapeutic multimodality. Gemcitabine is the effective first-line drug in pancreatic adenocarcinoma treatment. However, gemcitabine chemoresistance of pancreatic adenocarcinoma cells has been a major obstacle for limiting its treatment effect. Our study found that p70S6K1 plays an important role in gemcitabine chemoresistence. MiR-145 is a tumor suppressor which directly targets p70S6K1 for inhibiting its expression in pancreatic adenocarcinoma, providing new therapeutic scheme. Our findings revealed a new mechanism underlying gemcitabine chemoresistance in pancreatic adenocarcinoma cells.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

PubMed ID

27765914

Share

COinS